Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.3839
Abstract: Importance Recent national guidelines recommend sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD); yet, there are limited data on… read more here.
Keywords: disease; use; sodium glucose; sglt2i glp ... See more keywords
Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.42078
Abstract: Key Points Question What is the updated magnitude of benefit associated with sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) on outcome of cardiovascular death or hospitalization for heart failure (HHF) in different select subgroups of patients? Findings… read more here.
Keywords: cotransporter inhibitors; risk; sodium glucose; glucose cotransporter ... See more keywords
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.32584
Abstract: Key Points Question Is the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs glucagonlike peptide-1 receptor agonists (GLP-1 RAs) associated with dry eye disease among adults with type 2 diabetes (T2D)? Findings In this cohort… read more here.
Keywords: incidence; dry eye; eye; eye disease ... See more keywords
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.35995
Abstract: Key Points Question Is use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) associated with reduced risk of atrial fibrillation (AF) in older patients with type 2 diabetes? Findings In this US nationwide cohort study assessing the risk… read more here.
Keywords: fibrillation older; glucose cotransporter; type diabetes; cotransporter inhibitors ... See more keywords
Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.3303
Abstract: The long‐term impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on renal functions remains undefined. This study was undertaken to investigate the renal outcomes associated with SGLT2 inhibitors in patients with type 2 diabetes (T2DM)… read more here.
Keywords: term; sodium glucose; long term; outcomes associated ... See more keywords
Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function
Sign Up to like & getrecommendations! Published in 2020 at "ESC Heart Failure"
DOI: 10.1002/ehf2.12877
Abstract: Recent studies indicated that sodium glucose cotransporter‐2 inhibitors (SGLT2i) reduced heart failure hospitalization in patients with type 2 diabetes mellitus (T2DM). However, whether SGTL2i can improve left ventricular (LV) systolic and diastolic function remained unclear.… read more here.
Keywords: systolic function; sodium glucose; ventricular systolic; glucose cotransporter ... See more keywords
Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13483
Abstract: To systematically review randomized controlled trials assessing effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on hospitalization for heart failure (HHF) and cardiac structure/function and explore randomized controlled trial (RCT)‐derived evidence for SGLT2i efficacy mechanisms in… read more here.
Keywords: glucose cotransporter; heart; sodium glucose; heart failure ... See more keywords
Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13785
Abstract: Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI). read more here.
Keywords: transporter inhibitors; sodium glucose; heart; glucose transporter ... See more keywords
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13905
Abstract: We aimed to examine efficacy and safety outcomes of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) for the treatment of heart failure (HF), especially in patients with heart failure with preserved ejection fraction (HFpEF). read more here.
Keywords: sodium glucose; heart failure; heart; glucose cotransporter ... See more keywords
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2286
Abstract: In 2015, the first large‐scale placebo‐controlled trial designed to assess cardiovascular safety of glucose‐lowering with sodium–glucose co‐transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only… read more here.
Keywords: sodium glucose; cardiology; glucose transporter; heart failure ... See more keywords
Anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors in COVID-19.
Sign Up to like & getrecommendations! Published in 2023 at "IUBMB life"
DOI: 10.1002/iub.2719
Abstract: The ongoing pandemic of COVID-19 is intrinsically a systemic inflammatory disorder; hence, those patients suffering an underlying chronic inflammatory disease such as diabetes mellitus are at high risk of severe complications. Preventing or suppressing the… read more here.
Keywords: sodium glucose; glucose cotransporter; anti inflammatory; diabetic patients ... See more keywords